Show simple item record

dc.contributor.authorAlsaiari, Shahad K.
dc.contributor.authorQutub, Somayah S.
dc.contributor.authorSun, Shichao
dc.contributor.authorBaslyman, Walaa
dc.contributor.authorAldehaiman, Mansour M.
dc.contributor.authorAlyami, Mram Z.
dc.contributor.authorAlmalik, Abdulaziz
dc.contributor.authorHalwani, Rabih
dc.contributor.authorMerzaban, Jasmeen
dc.contributor.authorMao, Zhengwei
dc.contributor.authorAlsaiari, Shahad K.
dc.date.accessioned2021-01-31T10:57:57Z
dc.date.available2021-01-31T10:57:57Z
dc.date.issued2021-01-22
dc.date.submitted2020-09-09
dc.identifier.citationAlsaiari, S. K., Qutub, S. S., Sun, S., Baslyman, W., Aldehaiman, M., Alyami, M., … Khashab, N. M. (2021). Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy. Science Advances, 7(4), eabe7174. doi:10.1126/sciadv.abe7174
dc.identifier.issn2375-2548
dc.identifier.doi10.1126/sciadv.abe7174
dc.identifier.urihttp://hdl.handle.net/10754/667120
dc.description.abstractThe major impediments to the implementation of cancer immunotherapies are the sustained immune effect and the targeted delivery of these therapeutics, as they have life-threatening adverse effects. In this work, biomimetic metal-organic frameworks [zeolitic imidazolate frameworks (ZIFs)] are used for the controlled delivery of nivolumab (NV), a monoclonal antibody checkpoint inhibitor that was U.S. Food and Drug Administration–approved back in 2014. The sustained release behavior of NV-ZIF has shown a higher efficacy than the naked NV to activate T cells in hematological malignancies. The system was further modified by coating NV-ZIF with cancer cell membrane to enable tumor-specific targeted delivery while treating solid tumors. We envisage that such a biocompatible and biodegradable immunotherapeutic delivery system may promote the development and the translation of hybrid superstructures into smart and personalized delivery platforms.
dc.description.sponsorshipWe thank R. Langer, Institute Professor, MIT, for feedback and comments. We acknowledge H. Alrabiah, Associate Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University and H. I. Aljohar, Assistant Professor at the Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University for providing nivolumab.
dc.description.sponsorshipThis work was funded by the King Abdulaziz City for Science and Technology (KACST) through the MERS-CoV research grant program (number 20-0004), which is a part of the Targeted Research Program (TRP).
dc.publisherAmerican Association for the Advancement of Science (AAAS)
dc.relation.urlhttps://advances.sciencemag.org/lookup/doi/10.1126/sciadv.abe7174
dc.rightsThe Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.Government Works. Distributed under a Creative Commons Attribution Non Commercial License 4.0 (CC BY-NC).
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleSustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy
dc.typeArticle
dc.contributor.departmentAdvanced Membranes and Porous Materials Research Center
dc.contributor.departmentBiological and Environmental Sciences and Engineering (BESE) Division
dc.contributor.departmentBioscience Program
dc.contributor.departmentChemical Science Program
dc.contributor.departmentPhysical Science and Engineering (PSE) Division
dc.contributor.departmentSmart Hybrid Materials (SHMs) Laboratory, Advanced Membranes and Porous Materials Center, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
dc.contributor.departmentSmart Hybrid Materials (SHMs) lab
dc.identifier.journalScience Advances
dc.eprint.versionPublisher's Version/PDF
dc.contributor.institutionMOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China.
dc.contributor.institutionKey Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang 310009, China.
dc.contributor.institutionInstitute Center of Excellence in Nanomedicine (CENM), King Abdulaziz City for Science and Technology (KACST), Riyadh 11461, Saudi Arabia.
dc.contributor.institutionSharjah Institute for Medical Research (SIMR), Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
dc.identifier.volume7
dc.identifier.issue4
dc.identifier.pageseabe7174
kaust.personAlsaiari, Shahad K.
kaust.personQutub, Somayah S.
kaust.personBaslyman, Walaa
kaust.personAldehaiman, Mansour
kaust.personAlyami, Mram Zaid Ali
kaust.personMerzaban, Jasmeen S.
kaust.personKhashab, Niveen M.
dc.date.accepted2020-12-04
refterms.dateFOA2021-01-31T11:04:07Z


Files in this item

Thumbnail
Name:
eabe7174.full (1).pdf
Size:
3.888Mb
Format:
PDF
Description:
Publisher's version

This item appears in the following Collection(s)

Show simple item record

The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.Government Works. Distributed under a Creative Commons Attribution Non Commercial License 4.0 (CC BY-NC).
Except where otherwise noted, this item's license is described as The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S.Government Works. Distributed under a Creative Commons Attribution Non Commercial License 4.0 (CC BY-NC).